HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Maurice P. Brais William Goldstein Arvind Koshal Wilbert J. Keon Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brais, M. P. Articles by Keon, W. J. Search for Related Content PubMed PubMed Citation Articles by Brais, M. P. Articles by Keon, W. J.

Ann Thorac Surg 1985;39:105-111
© 1985 The Society of Thoracic Surgeons

---

Articles

Ionescu-Shiley Pericardial Xenografts: Follow-up of Up to 6 Years

Presented at the Joint Annual Scientific Sessions of the Royal College of Physicians and Surgeons of Canada and the Canadian Society of Cardiovascular and Thoracic Surgeons, Calgary, Alberta, Canada, Sept 21, 1983

Accepted for publication July 2, 1984.

^* Address reprint requests to Dr. Brais, University of Ottawa Heart Institute, Ottawa Civic Hospital, 1053 Carling Ave, Ottawa, Ont, Canada K1Y 4E9

The results of valve replacement with the Ionescu-Shiley pericardial xenograft compare favorably with results obtained with other bioprostheses. From March, 1977, to July, 1983, 497 Ionescu-Shiley pericardial valves were implanted in 463 patients at the University of Ottawa Heart Institute. There were 292 patients who had aortic valve replacement (AVR), 140 with mitral valve replacement (MVR), 28 with double valve replacement, and 3 with triple valve replacement. The survivors were followed regularly. Actuarial analysis of late results indicates an expected survival of 71% at 6 years for patients who underwent AVR and 72% at 3 years for patients who had MVR. The only valve-related deaths were due to endocarditis, which occurred at a rate of 3.9% per patient-year for aortic valves and 0.6% per patient-year for mitral valves. Despite a low usage of formal anticoagulation, embolic complications occurred at a rate of 1.4% per patient-year for aortic valves and 4.0% per patient-year for mitral valves. Five valves were removed for intrinsic failure after 36 to 72 months of follow-up. New York Heart Association Functional Class improved an average of 1.28 classes per patient.

This article has been cited by other articles:

				D. M. Cosgrove, B. W. Lytle, P. C. Taylor, M. T. Camacho, R. W. Stewart, P. M. McCarthy, D. P. Miller, M. R. Piedmonte, and F. D. Loop The Carpentier-Edwards pericardial aortic valve: Ten-year results J. Thorac. Cardiovasc. Surg., September 1, 1995; 110(3): 651 - 662. [Abstract] [Full Text]

				W. Daenen, L. Noyez, E. Lesaffre, Y. Goffin, and G. Stalpaert The Ionescu-Shiley Pericardial Valve: Results in 473 Patients Ann. Thorac. Surg., November 1, 1988; 46(5): 536 - 541. [Abstract] [PDF]

				L. H. Edmunds Jr. Thrombotic and Bleeding Complications of Prosthetic Heart Valves Ann. Thorac. Surg., October 1, 1987; 44(4): 430 - 445. [Abstract] [PDF]

				J. Fisher, I. J. Reece, G. R. Jack, L. Cathcart, and D. J. Wheatley Laboratory Assessment of the Design, Function, and Durability of Pericardial Bioprostheses Engineering in Medicine, April 1, 1987; 16(2): 105 - 109. [Abstract] [PDF]

				G. Golomb Controlled Release of Diphosphonates from Synthetic Polymers to Inhibit Calcification J Biomater Appl, January 1, 1987; 2(2): 266 - 289. [Abstract] [PDF]